Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the potential of desoximetasone 0.25% topical
spray to suppress HPA axis function. The potential for adrenal suppression will be assessed
following multiple dosing with Desoximetasone 0.25% Topical Spray in patients with moderate
to severe plaque psoriasis. The secondary objectives are to evaluate the efficacy parameters
and to evaluate the adverse event (AE) profile.